Apixaban (Eliquis), dabigatran (Pradaxa), Edoxaban (Lixiana) and rivaroxaban (Xarelto) are anticoagulants licensed in varying doses in adults for prevention and treatment of venous thromboembolism and for non-valvular atrial fibrillation.

These agents were previously known as NOACs (Novel Oral Anticoagulants)

Safety Alert Direct Oral Anticoagulants (DOACs) – May 2018

Please also note availability of a Patient Information Video for DOACs